Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT – Research Report) and Mind Medicine (MNMD – Research Report) with bullish sentiments.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Corcept Therapeutics (CORT)
In a report issued on December 30, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics, with a price target of $50.00. The company’s shares closed last Wednesday at $34.80.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Corcept Therapeutics with a $110.20 average price target.
See the top stocks recommended by analysts >>
Mind Medicine (MNMD)
Mind Medicine received a Buy rating and a $20.00 price target from Chardan Capital analyst Rudy Li yesterday. The company’s shares closed last Wednesday at $13.39.
According to TipRanks.com, Li is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mind Medicine with a $30.80 average price target, a 138.4% upside from current levels. In a report issued on December 23, JonesTrading also initiated coverage with a Buy rating on the stock with a $61.00 price target.
